Similar articles

• The role of biliary excretion in the hepatotoxicity of furosemide in the mouse.

  Spitznagle LA, Wirth PJ, Boobis SW, Thorgeirsson SS, Nelson WL. Spitznagle LA, et al. Toxicol Appl Pharmacol. 1977 Feb;39(2):283-94. doi: 10.1016/0041-008x(77)90161-2. Toxicol Appl Pharmacol. 1977. PMID: 847756 No abstract available.
• A comparative diuretic and tissue distribution study of bumetanide and furosemide in the dog.

  Cohen MR, Hinsch E, Vergona R, Ryan J, Kolis SJ, Schwartz MA. Cohen MR, et al. J Pharmacol Exp Ther. 1976 Jun;197(3):697-702. J Pharmacol Exp Ther. 1976. PMID: 932999
• Quantitative determination of furosemide in plasma, plasma water, urine and ascites fluid by high-performance liquid chromatography.

  Uchino K, Isozaki S, Saitoh Y, Nakagawa F, Tamura Z, Tanaka N. Uchino K, et al. J Chromatogr. 1984 Jun 8;308:241-9. doi: 10.1016/s0021-9673(01)87550-6. J Chromatogr. 1984. PMID: 6746817
• Clinical pharmacokinetics of frusemide.

  Cutler RE, Blair AD. Cutler RE, et al. Clin Pharmacokinet. 1979 Jul-Aug;4(4):279-96. doi: 10.2165/00003088-197904040-00002. Clin Pharmacokinet. 1979. PMID: 385209 Review. No abstract available.
• Aspects of the clinical pharmacology of non-steroidal anti-inflammatory drugs.

  Graham GG, Day RO, Champion GD, Lee E, Newton K. Graham GG, et al. Clin Rheum Dis. 1984 Aug;10(2):229-49. Clin Rheum Dis. 1984. PMID: 6439458 Review. No abstract available.